Aprepitant

精彩内容 日前，河南省医药集采平台发布《关于公示2024年10月通过绿色通道增补挂网药品的通知》，5个产品位列其中，包括2款1类新药——用于复发或转移性宫颈癌的PD-1抑制剂恩朗苏拜单抗注射液、以及治疗急性气管-支气管炎的独家中成药九味止咳口服液。米内网数据显示，2023年中国公立医疗机构终端抗肿瘤药、止咳祛痰平喘用药销售额分别超1100亿元和160亿元。 来源：河南省医药集采平台恩朗苏拜单抗注射液由石药集团研发，是一款重组抗PD-1全人源单克隆抗体，用于既往接受含铂化疗治疗失败的PD-L1表达阳性（CPS≥1）的复发或转移性宫颈癌患者。在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端，抗肿瘤药2023-2024H1销售额分别突破1100亿元、630亿元，同比增长3.96%和8.6%。2024年至今，石药集团已有11个品种获批上市，包括1类新药恩朗苏拜单抗注射液、2类改良型新药注射用重组人TNK组织型纤溶酶原激活剂、3.3类生物类似药注射用奥马珠单抗，以及注射用两性霉素B脂质体、阿瑞匹坦注射液、注射用右雷佐生等8款高端仿制药。今年以来石药集团获批上市的新品来源：米内网中国申报进度（MED）数据库九味止咳口服液是卓和药业的1.1类中药新药，具有宣肺止咳之功，用于急性气管-支气管炎中医辨证属风热证的咳嗽，伴见咳痰、咽干，舌红苔薄黄、脉浮数或浮滑。目前该药已通过2024国谈形式审查，最终能否纳入新一批医保目录，11月有望见分晓。米内网数据显示，2021-2023年中国公立医疗机构终端止咳祛痰平喘用药销售额均突破100亿元，2023年更拿下创新高的超160亿元，同比涨逾47%；2024H1虽略有回落，但仍有超77亿元的销售额进账，市场潜力值得期待。近年来中国公立医疗机构终端止咳祛痰平喘用药销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局此外，还有3款药品拟通过绿色通道增补挂网，分别为洋浦京泰药业的多种微量元素注射液(Ⅲ)、美诺华天康药业的艾曲泊帕乙醇胺片和甫康健康科技的马来酸奈拉替尼片，涵盖消化系统及代谢药、血液和造血系统药物、抗肿瘤和免疫调节剂等治疗大类，拟增补挂网理由均为：属申报价格低于支付标准的国谈仿制药。拟通过绿色通道增补挂网的药品（单位：元） 来源：米内网数据库、河南省医药集采平台注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至10月25日，如有疏漏，欢迎指正！ 本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。 投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。 把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下： 【分享、点赞、在看】点一点不失联哦

SAN DIEGO, Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage. As widely reported, the potential disruption in the supply of intravenously administered fluids is a result of the temporary closure of a major suppliers' manufacturing site in Marion, North Carolina which was impacted by Hurricane Helene. The Marion facility is believed to supply up to 60% of the IV fluid market in the U.S. "In the wake of Hurricane Helene, and with the recently announced potential supply disruption for IV fluids, Heron has received outreach from several health systems preparing to maintain continuity of care," said Craig Collard, Chief Executive Officer of Heron. "Our team is committed to ensuring timely delivery of our products throughout the U.S. during the potential shortage of IV fluids as we understand the importance of preventing CINV and PONV for both patients and providers." CINVANTI, SUSTOL, and APONVIE are available through major wholesalers and specialty distributors, and further information can be obtained by calling the Company's information line at 844-HERON11 (844-437-6611). About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules. Aprepitant (including its prodrug, fosaprepitant) is a single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection. Please see full prescribing information at . About SUSTOL for CINV Prevention SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron's Biochronomer® drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL's efficacy and safety in more than 2,000 patients with cancer. SUSTOL's efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy). Please see full prescribing information at . About APONVIE for Postoperative Nausea and Vomiting (PONV) APONVIE is a substance NK1 Receptor Antagonist (RA), indicated for the prevention of PONV in adults. Delivered via a 30-second IV push, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of therapeutic drug levels. APONVIE is the same formulation as Heron's approved drug product CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023. Please see full prescribing information at . About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for APONVIE®, CINVANTI® and SUSTOL®. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED